<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">YOSHIOKA, TAKASHI</style></author><author><style face="normal" font="default" size="100%">TAKAHASHI, MASANOBU</style></author><author><style face="normal" font="default" size="100%">SAKAMOTO, YASUHIRO</style></author><author><style face="normal" font="default" size="100%">OKITA, AKIRA</style></author><author><style face="normal" font="default" size="100%">FUKUI, TADAHISA</style></author><author><style face="normal" font="default" size="100%">MURAKAWA, YASUKO</style></author><author><style face="normal" font="default" size="100%">SHINDO, YOSHIAKI</style></author><author><style face="normal" font="default" size="100%">IMAI, HIROO</style></author><author><style face="normal" font="default" size="100%">OHORI, HISATSUGU</style></author><author><style face="normal" font="default" size="100%">SHIROTA, HIDEKAZU</style></author><author><style face="normal" font="default" size="100%">CHIBA, NATSUKO</style></author><author><style face="normal" font="default" size="100%">SASAHARA, YURIKO (ITO)</style></author><author><style face="normal" font="default" size="100%">NOMURA, TAKASHI</style></author><author><style face="normal" font="default" size="100%">FUKUSHIMA, NORIMASA</style></author><author><style face="normal" font="default" size="100%">YAMAGUCHI, TAKUHIRO</style></author><author><style face="normal" font="default" size="100%">SHIMODAIRA, HIDEKI</style></author><author><style face="normal" font="default" size="100%">ISHIOKA, CHIKASHI</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2009-2015</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.15680</style></doi><volume><style face="normal" font="default" size="100%">42</style></volume><issue><style face="normal" font="default" size="100%">4</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: This phase II study assessed the efficacy of capecitabine plus cisplatin in patients with advanced gastric cancer refractory to adjuvant S-1. Patients and Methods: This single-arm, open-label, multicenter, phase II study was conducted by Tohoku Clinical Oncology Research and Education Society (T-CORE) in Japan. Patients aged ≥20 years with advanced HER2-negative gastric cancer that was refractory to S-1 were enrolled. Patients received 80 mg/m2 cisplatin on day 1 intravenously and 1,000 mg/m2 capecitabine twice daily from day 1 to day 14, in 3-week cycles. The primary endpoint was progression-free survival (PFS). The threshold overall response rate (ORR) was estimated to be 15%. The secondary endpoints were overall survival (OS), time to treatment failure, ORR, and toxicities. Results: In total, 21 patients were enrolled from seven hospitals. The median patient age was 63 years. Nineteen patients received the protocol treatment. Median PFS was 3.7 months [90% confidence interval (CI)=2.7-5.6 months], which did not reach the predefined threshold of 4.0 months. ORR was 5.9% (95%CI=0.0-17.1%). Median OS was 11.9 months (95% CI 6.3-19.4 months). Febrile neutropenia was observed in 5.3% of patients. The most frequently observed grade 3 non-hematologic toxicities were nausea (15.8%) and hyponatremia (15.8%). Conclusion: The addition of a fluoropyrimidine to a platinum agent after adjuvant therapy is not suitable for gastric cancer.</style></abstract></record></records></xml>